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Abstract 
Sleep and electroencephalogram abnormalities are prominent early features of Huntington’s 
disease (HD) that typically appear before the onset of characteristic motor symptoms. The 
changes in sleep and electroencephalogram  seen in HD patients are largely recapitulated in 
mouse models of HD such as transgenic R6/2 lines. To test whether or not drugs with 
hypnotic properties can correct the sleep and electroencephalogram  abnormalities seen in 
HD mice, we treated male wild-type (WT; N=7) and R6/2 mice (N=9) acutely with 
intraperitoneal injections of vehicle, zolpidem (5, 10 or 20 mg/kg) or amitriptyline (5, 10 or 
20 mg/kg), and then monitored their sleep–wake behavior. In R6/2 mice, both zolpidem and 
amitriptyline suppressed the abnormally high REM sleep amount and 
electroencephalographic  gamma (30-46 Hz) oscillations in a dose-dependent manner. 
Amitriptyline’s effect on sleep was similar in both genotypes, whereas zolpidem showed 
significant genotype differences. Zolpidem exerted a strong hypnotic effect in WT mice by 
increasing electroencephalographic  delta power, doubling the mean bout duration and the 
total amount of non-rapid eye movement sleep. However, no such effect was seen in R6/2 
mice. Our study demonstrates that the pathophysiological changes seen in sleep and 
electroencephalogram  are not ‘hard-wired’ in HD brain and can be reversed even at late 
stages of the disease. The diminished hypnotic effect of zolpidem suggests that the 
GABAergic control of sleep–wake states is impaired in HD mice. A better understanding of 
the neurochemical basis underlying these abnormalities should lead to more effective and 
rational therapies for HD. 
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1. Introduction 
The mutation causing Huntington's disease (HD) was discovered more than 20 years ago (1), 
yet an effective treatment to either prevent or slow the progression of the disease remains 
elusive. HD is best known as a movement disorder, but patients often show non-motor 
symptoms such as cognitive and psychiatric dysfunctions well before the onset of 
characteristic motor signs (2). Sleep and electroencephalogram (EEG) abnormalities are also 
prominent early features of HD that are often under-diagnosed (3). HD patients as well as 
pre-manifest gene carriers have shallow and fragmented night-time sleep, abnormal rapid eye 
movement (REM) sleep, and abnormally increased low-gamma oscillations in their sleep 
EEG (4-7). The changes in sleep and EEG seen in HD patients are largely recapitulated in 
mouse models of HD. For instance; we have shown previously that the R6/2 mouse, one of 
the best-characterized animal models of HD, has fragmented sleep-wake cycle and an 
increased propensity for REM sleep (8). In addition, EEG delta power decreases, whereas an 
abnormal low-gamma oscillation emerges in the sleep EEG of R6/2 mice well before the 
onset of any motor symptoms (8). Similar results have been found by other groups in R6/2 
(9-11) and R6/1 transgenic mice (12-14), as well as in Q175 knock-in mouse models of HD 
(15-17). 
Although there is a great demand for an effective therapy, only tetrabenazine is 
currently licensed as a treatment for excess chorea in HD (18). In clinical practice, on the 
other hand, many other medications are used for symptomatic treatment of HD, including a 
number of hypnotics and antidepressants (18). It is unknown whether or not such drugs have 
any effect on HD-specific sleep and EEG symptoms (3). The gamma-aminobutyric acid 
(GABA) A receptor modulator zolpidem and the tricyclic antidepressant amitriptyline are 
commonly prescribed for the treatment of sleep disturbances and depression in HD patients 
(18, 19). Both drugs display strong hypnotic properties in healthy humans and rodents (20-
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23) but their effect on HD specific sleep and EEG symptoms has not yet been studied. To 
gain insight into the neurochemical basis underlying sleep and EEG abnormalities seen in HD 
as well as to test whether these abnormalities can be corrected by drugs, we treated R6/2 mice 
with zolpidem or amitriptyline at a symptomatic stage of the disease. We found that acute 
treatment with both of these drugs can normalize many of the sleep and EEG abnormalities 
present in R6/2 mice. 
 
2. Materials and methods  
2.1 Animals and housing conditions 
All experiments were conducted under the authority of the United Kingdom Animals 
(Scientific Procedures) Act 1986. Male R6/2 (N = 9) and wild type (WT; N = 7) littermate 
mice were taken from a colony established at the University of Cambridge (CBAxC57/BL6 
background). Genotyping and repeat length measurements were performed by Laragen (Los 
Angeles, CA). Genotyping was performed by PCR from tail snips taken at 3 weeks of age. 
CAG repeat lengths were measured by GeneMapper software (Life Technologies, NY). R6/2 
mice had a mean CAG repeat length of 253 ± 2. We have shown that up to ~300 CAG 
repeats, the basic pathology and end-stage symptoms differ little from the 110 CAG repeats 
in the R6/2 mice. The main difference is the rate of progression of disease. Whereas 110 
CAG repeat mice die at around 12-14 weeks of age, 250 CAG repeat R6/2 mice live until 
around 20-24 weeks (24-26). Before the end of study, one WT and one R6/2 mouse lost their 
EEG/EMG implants and were euthanized. In addition, one WT mouse died unexpectedly and 
two R6/2 mice died of their disease. Successful EEG/EMG recordings with all treatments 
were achieved in five out of seven WT mice and six out of nine R6/2 mice. Additional 
recordings were obtained in the remaining mice after some of the treatments (for further 
details see 2.3). 
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2.2 Surgery and EEG/EMG recordings 
We implanted each mouse with EEG and EMG electrodes under isoflurane anesthesia (1.5-
2%), as described previously (8). Briefly, we placed gold-plated stainless steel screw 
electrodes epidurally over the frontal (1.5 mm lateral and 1.0 mm anterior to bregma) and 
parietal (1.5 mm lateral and 1.0 mm anterior to lambda) cortex, above both left and right 
hemispheres for fronto-parietal EEG recordings. EMG signals were acquired by a pair of 
stainless steel spring wires (Plastics One Inc., Roanoke, VA) inserted into the neck extensor 
muscles (8). Before implantation, each screw was soldered to a soft insulated stainless steel 
wire, and all cables were connected to a single common eight-pin connector compatible with 
the data recording system (Pinnacle Technology, Lawrence, KS). Cables and the connector 
were all fixed to the skull with dental cement. 
After surgery, we housed the mice in individual recording cages (with food and water 
available ad libitum) within sound-attenuating chambers with a 12:12 h light-dark cycle (30 
lux daylight-type fluorescent tubes with lights on at 06:00), constant temperature (22 ± 1°C) 
and humidity (55 ± 10%). After a recovery period of 7-10 days, we connected the mice to 
recording cables. The recording cable was attached to a low torque electrical swivel above 
the cage that allowed free movement. After mice acclimated to the recording conditions for 
3-4 days, we recorded EEG and EMG signals for 24h after each treatment. The mice 
remained connected to the recording cable throughout the study.  
 The EEG/EMG signals were amplified and filtered (EEG: 0.5-60 Hz, EMG: 10-100 
Hz) by head-mounted preamplifiers and amplifiers (8202-DSL and 8206-SL, respectively; 
Pinnacle Technology, Lawrence, KS), and recorded on a computer (Vital Recorder, Kissei 
Comtec, Matsumoto, Japan) after analog-to-digital conversion. 
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2.3 Drug Administration 
Zolpidem (Tocris, Bristol, UK) was dissolved in 10% dimethyl sulfoxide / 5 mM citric acid 
in saline (zolpidem vehicle). Amitriptyline (Sigma-Aldrich, Dorset, UK) was dissolved in 
saline (amitriptyline vehicle). Both zolpidem and amitriptyline display strong hypnotic 
properties (20-23). Thus to avoid a potential ‘ceiling effect’, where measured variables are at 
their maximum already under control conditions, we injected the mice just before dark onset 
and assessed the hypnotic potential of these drugs during the active dark period. The mice 
were given intraperitoneal (i.p.) injection in a volume of 10 ml/kg body weight. We treated 
the mice with three doses of zolpidem (5, 10, or 20 mg/kg), three doses of amitriptyline (5, 
10, or 20 mg/kg), and their vehicles in a cross-over design with 2-3 days between the 
treatments. These doses were chosen based on the literature (20-23) and our pilot 
experiments. The different doses of a drug (zolpidem or amitriptyline) and its vehicle were 
given in a randomized order to the mice. The mice received zolpidem at 14-15 weeks of age 
and amitriptyline at 16-17 weeks of age. Five out of seven WT mice received all the 
treatments. The other two WT mice received all treatments apart from either the 5 mg/kg 
dose (one mouse) or the 10 mg/kg dose of amitriptyline (one mouse). Six out of nine R6/2 
mice received all the treatments. Of the other three mice, two R6/2 mice received all doses of 
zolpidem and its vehicle, one R6/2 mouse received the 10 and 20 mg/kg doses of zolpidem 
and vehicle, but none of these mice received amitriptyline. 
 
2.4 Data analysis and statistics 
All signals were digitized at 256 Hz, digitally filtered (EEG: 0.5-60 Hz and EMG: 10-60 Hz), 
and semi-automatically scored as wake, non-REM (NREM) sleep, or REM sleep in 10 s 
epochs using SleepSign (Kissei Comtec, Matsumoto, Japan). Experienced scorers, blinded to 
treatment and genotype, visually inspected these preliminary scorings and made corrections 
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when appropriate. We then measured the duration of bouts, counted the number of bouts, and 
calculated the percentage of time spent in each behavioral state. 
To reveal the changes in the frequency content of the recorded signal, we performed a 
spectral analysis of the EEG after the treatments. EEG power spectra were computed for 
consecutive 2 s epochs in the frequency range 0.5 to 49 Hz by fast Fourier transformation 
with a frequency resolution of 0.5 Hz. Before fast Fourier transformation, a window 
weighting function (Hanning) was applied. Epochs with movement-induced and other 
artifacts were discarded on the basis of the polygraph records. Data are presented in 1 Hz 
bins, where the bins were marked by their upper limits. The values of consecutive 2 s EEG 
epochs in wake, NREM and REM sleep, respectively, were averaged over 2 h after zolpidem 
and over 3 h after amitriptyline treatments. 
To reveal the changes in higher frequency bands after the treatments, in addition to 
analyzing the entire EEG spectrum (1-49 Hz), we also compared the discrete changes in the 
low-gamma range (30-46 Hz) of the EEG.  Finally, to reveal the differences between the 
groups, we normalized the EEG power spectral values of R6/2 mice to the mean power 
spectral values of vehicle-treated WT mice of the same age. 
To compare statistically the raw EEG data and vigilance state parameters, we used 
multivariate analysis of variance with repeated measures and Bonferroni test for post hoc 
comparisons (Statistica 12, Statsoft, Tulsa, OK). The results were considered statistically 
significant at P < 0.05. All results are expressed as means ± SEM. 
 
3. Results 
3.1 Zolpidem is less potent hypnotic in HD mice than in WT mice 
At 14-15 weeks of age, R6/2 mice already have an increased propensity for REM sleep and a 
fragmented sleep-wake pattern comparted to WT mice (8, 10). The effect of zolpidem (20 
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mg/kg) on vigilance states was seen only in the first 2-3 hours after treatment (Fig. 1). This is 
consistent with the short half-life of the drug (27). In R6/2 mice, zolpidem (10 and 20 mg/kg) 
reduced the abnormally increased REM sleep amount by half [drug x genotype interaction: 
F(3,39) = 3.27, P < 0.05, Fig. 2C], but had no significant effect on REM sleep in WT mice 
(Fig. 2C). Furthermore, zolpidem decreased the time spent awake and increased the amount 
of NREM sleep in a dose-dependent manner in both WT and R6/2 mice during the first 3 h 
post-treatment [drug effects: F(3,39) = 25.66, P < 0.01 and F(3,39) = 29.84, P < 0.01, 
respectively; Fig. 2A and B]. Compared to vehicle treatment, zolpidem doubled the amount 
of NREM sleep at its highest dose (20 mg/kg) and it was hypnotic even at its lowest dose (5 
mg/kg) in WT mice (Fig. 2B). By contrast, zolpidem was less hypnotic in R6/2 mice as even 
at its highest dose (20 mg/kg) it increased NREM sleep amount only by about 40% (Fig. 2B). 
The difference in the hypnotic effect of zolpidem in WT and R6/2 mice was even more 
obvious when we compared the mean duration of sleep-wake bouts. In WT mice, zolpidem 
(20 mg/kg) consolidated NREM sleep by doubling the mean duration of NREM sleep bouts 
[drug effect: F(3,39) = 8.31, P < 0.01; Table 1]. Zolpidem (20 mg/kg) also reduced the mean 
duration of awakenings in WT mice by almost half during this time [drug effect: F(3,39) = 
9.30, P < 0.01; Table 1]. By contrast, the mean duration of sleep-wake bouts did not change 
significantly in R6/2 mice after zolpidem treatment. 
 
3.2 Zolpidem suppresses the abnormal low-gamma EEG oscillations during NREM sleep 
By 14-15 weeks of age, R6/2 mice had twice as much low-gamma activity (with a peak at 39-
40 Hz) in their NREM sleep EEG as did WT mice under control conditions (Fig. 3D). 
Zolpidem decreased these abnormal low-gamma oscillations in NREM sleep EEG in a dose-
dependent manner during the first two hours after the treatment. The 20 mg/kg dose of 
zolpidem reduced these abnormal low-gamma oscillations by about half in R6/2 mice in the 
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first 2 h after treatment [drug x frequency interaction: F(48,336) = 5.53, P < 0.01; Fig. 3B’ and 
D]. The higher doses of zolpidem (10 and 20 mg/kg) also decreased EEG theta power (5-10 
Hz) during NREM sleep in both WT and R6/2 mice [drug x frequency interactions: F(144,864) = 
2.21, P < 0.01 and F(144,1008) = 4.03, P < 0.01, respectively; Fig. 3A and B]. The lowest dose 
of zolpidem (5 mg/kg) increased delta power (1-4 Hz) during NREM sleep in WT mice [drug 
x frequency interactions: F(144,864) = 2.21, P < 0.01; Fig. 3A and C] but not in R6/2 mice. The 
changes in REM sleep EEG in R6/2 mice were not significant (Fig. 4). 
 
3.3 Amitriptyline reduces REM sleep amount and consolidates NREM sleep 
Despite the fact that under control conditions R6/2 mice had four times as much REM sleep 
as was seen in WT mice, amitriptyline abolished REM sleep to the same extent in both WT 
and R6/2 mice. The effect lasted for several hours (Fig. 5), and was dose-dependent (Fig. 6).  
In the first 6 h after the treatment, amitriptyline (20 mg/kg) decreased the amount of REM 
sleep by about 90% in both WT and R6/2 mice compared to vehicle treatment [drug effect: 
F(3,27) = 28.18, P < 0.01; drug x genotype interaction: F(3,27) = 11.95, P < 0.01; Fig. 6]. This 
was achieved primarily by suppressing the initiation of REM sleep as shown by the reduction 
in bout numbers. After vehicle treatment, WT mice had five to six bouts while R6/2 mice had 
20-21 bouts of REM sleep on average. By contrast, WT mice entered into REM sleep only 
once, or not at all after amitriptyline (20 mg/kg) treatment. Similarly, R6/2 mice entered into 
REM sleep fewer than four times within a 6 h period after the drug. That is more than 80% 
fewer REM sleep bouts after amitriptyline (20 mg/kg) than was seen under control condition 
in both genotypes [drug x genotype interaction: F(3,27) = 7.65, P < 0.01; Table 2]. 
Interestingly, while the propensity for initiating REM sleep was suppressed, the maintenance 
of REM sleep was not affected, as the mean duration of REM sleep bouts did not change 
significantly in either genotype after amitriptyline treatment (Table 2). 
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The hypnotic effect of amitriptyline was dose-dependent in both WT and R6/2 mice. At 
the 20 mg/kg dose, amitriptyline nearly doubled the amount of NREM sleep in WT mice and 
increased it by about 60% in R6/2 mice during the first 6 h after the treatment [drug effect: 
F(3,27) = 34.64, P < 0.01; Fig. 6]. NREM sleep also became less fragmented in R6/2 mice, 
with NREM sleep bouts being more than twice as long after amitriptyline (20 mg/kg) 
treatment than they were under the control condition [drug x genotype interaction: F(3,27) = 
5.33, P < 0.01; Table 2]. At the same time, the amount of wakefulness was reduced by more 
than half in both WT and R6/2 mice after the 20 mg/kg dose of amitriptyline [drug effect: 
F(3,27) = 23.44, P < 0.01; Fig. 6]. This reduction in total wake amount was due to the 
shortening of wake bouts (WT mice: -71.2 % and R6/2 mice: -45.2%) since the number of 
wake bouts did not change significantly (Table 2). The inability of mice to maintain long 
periods of wakefulness together with the increased amount of NREM sleep indicate strong 
sedative-hypnotic properties of the drug at the highest dose tested (20 mg/kg).  
 
3.4 Amitriptyline corrects abnormal low-gamma EEG oscillations in HD mice 
Since amitriptyline virtually abolished REM sleep in both WT and R6/2 mice for several 
hours (Fig. 5), we could only analyze the changes in EEG power spectra during NREM sleep 
after the treatment. After analyzing the time course of changes, we found that amitriptyline 
dose-dependently decreased the abnormal low-gamma oscillations in NREM sleep EEG in 
R6/2 mice for 3 h [drug x frequency interaction: F(48,240) = 5.62, P < 0.01; Fig. 7B’]. Under 
control conditions, 16-17 weeks old R6/2 mice had a fourfold increase in EEG low-gamma 
activity compared to WT mice, with a peak frequency at 36-37 Hz (Fig. 7D). The highest 
dose (20 mg/kg) of amitriptyline decreased these abnormal low-gamma oscillations in R6/2 
mice close to the level of control treated WT mice (Fig. 7D). Compared to vehicle, the 20 
mg/kg dose of amitriptyline also shifted nearly the entire EEG spectrum down, with 
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differences reaching significance at 8 Hz in WT mice and 7-9 Hz in R6/2 mice [drug x 
frequency interactions: F(144,576) = 5.58, P < 0.01 and F(144,720) = 4.12, P < 0.01, respectively; 
Fig. 7A and B]. In contrast to the 20 mg/kg dose, lower doses of amitriptyline (5 and 10 
mg/kg) increased low frequency oscillations in NREM sleep EEG at 1-5 Hz in WT mice and 
at 3-7 Hz in R6/2 mice compared to vehicle (Fig. 7A and B). These opposite changes in the 
EEG spectrum suggest that high doses of amitriptyline produce non-specific as well as 
specific effects, although the effect of amitriptyline on abnormal low-gamma oscillations was 
consistent across all doses in R6/2 mice. 
 
4. Discussion 
We show for the first time that the sleep and EEG abnormalities found in HD mice can be 
reversed after a single treatment with zolpidem or amitriptyline. In R6/2 mice, zolpidem 
reduced the abnormally increased REM sleep amount and the abnormal low-gamma 
oscillations in NREM sleep EEG by half. Amitriptyline abolished REM sleep as well as the 
abnormal low-gamma EEG oscillations in R6/2 mice for several hours. Both drugs increased 
the amount of NREM sleep and decreased the time spent awake, in both WT and R6/2 mice.  
Amitriptyline and zolpidem are both prescribed to HD patients for the treatment of 
depression and sleep disturbances (18, 19). HD patients as well as pre-manifest gene carriers 
have shallow and fragmented night-time sleep, and abnormal REM sleep (4-7). R6/2 mice 
also have a fragmented sleep–wake pattern and an abnormal increase in REM sleep amount 
during their active dark period (8, 10). Though amitriptyline had a more robust and longer 
lasting effect than zolpidem, both drugs reduced the amount of REM sleep and wakefulness, 
and increased the time spent in NREM sleep in both WT and R6/2 mice in our study. Similar 
results have been found by others in both humans and rodents after acute treatment with 
zolpidem or amitriptyline (20-23). Although, repeated administration of these drugs can 
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result different effect. For instance, most of antidepressants suppress REM sleep early in 
treatment, but this effect gradually diminishes after their repeated administration (28, 29). 
The ability of zolpidem and amitriptyline to suppress REM sleep in R6/2 mice is particularly 
interesting, since R6/2 mice had more than twice as much REM sleep during the active dark 
period as WT mice. REM sleep is generated by neurons primarily located in the brain stem 
(30, 31), although other brain sites such as the ventrolateral periaqueductal grey matter or the 
lateral hypothalamic area may also be relevant (32, 33). We have suggested previously that 
the incomplete suppression of REM sleep in HD mice during the active period may be a 
result of an abnormally functioning orexin system (8). The changes in REM sleep induced by 
zolpidem and amitriptyline in R6/2 mice suggest that although the primary REM sleep 
regulatory circuits cannot efficiently suppress the initiation of REM sleep during the active 
period they are still functional and can be modulated by drugs in HD mice.  
Although zolpidem efficiently reduced REM sleep in both genotypes, it proved to be less 
hypnotic in R6/2 mice than it was in WT mice. The zolpidem-induced increase in NREM 
sleep lasted for 3 h in WT mice but it was limited to the first hour post-treatment in R6/2 
mice. Also, whereas zolpidem consolidated sleep in WT mice by lengthening NREM sleep 
episodes, shortening awakenings and increasing EEG delta power during NREM sleep, no 
such effect was seen in R6/2 mice. The reduced efficacy of zolpidem in R6/2 mice suggests 
impairment in the GABAergic control of sleep-wakefulness. In accordance with this idea, 
decreased GABAergic neurotransmission is found in the frontal and parietal cortices, as well 
as in various parts of the basal ganglia such as the globus pallidus (GP) of symptomatic R6/2 
mice (34). GABAergic neurons of GP externus (GPe) project directly to layer V neurons of 
the neocortex (35-38), which seems to play a critical role in slow wave sleep generation (39). 
Since GP neurons are most active when the neocortex is activated, such as during 
wakefulness and REM sleep (40), the corticopetal GPe neurons are likely to promote sleep by 
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suppressing cortical activity and inhibiting fast cortical oscillations (41). Indeed, optogenetic-
stimulation of GPe neurons increased sleep and EEG delta power (42), while lesion of GP 
decreased sleep and increased sleep-wake fragmentation in laboratory rats (43). GP neurons 
receive inhibitory inputs from the striatum, and although the concentration of GABA is 
normal in R6/2 mouse striatum (44), striatal neurons are hyperactive in symptomatic R6/2 
mice (45). Thus, based on the above, it seems very likely that an increased striatal inhibition 
of pallidocortical projections in R6/2 mice could lead to a disinhibition of layer V cortical 
neurons (Fig. 8). As a result, increased cortical activity would occur in R6/2 mice regardless 
of vigilance state. This could account for the fragmented sleep, decreased EEG delta power, 
and increased REM sleep amount seen in R6/2 mice, and would also explain the reduced 
hypnotic efficacy of zolpidem in these mice. Insufficient inhibition of cortical activity by 
cortical-projecting GP neurons could also account for at least some of the EEG irregularities 
seen in R6/2 mice, such as the increased low-gamma oscillations during sleep. 
Gamma oscillations are primarily generated by networks of glutamatergic and 
GABAergic interneurons of the cortex, and controlled by cortically projecting GABAergic 
neurons of the basal forebrain (46). These gamma oscillations normally occur during states of 
activated neocortex such as wakefulness and REM sleep (47, 48). In schizophrenic patients, 
abnormal EEG gamma oscillations can be seen during periods of psychosis and sleep (49). 
The fact that abnormal EEG gamma oscillations occur in R6/2 mice during synchronized or 
deactivated state of neocortex (8, 10, 11) also supports the idea of an insufficient inhibition of 
cortical activity in HD. The striatum, which receives many of its inputs from the neocortex 
(Fig. 8), also shows abnormal low-gamma oscillations in R6/2 mice during quiet rest (9, 50). 
Furthermore, abnormally increased low-gamma oscillations have been found recently in the 
sleep EEG of early HD patients (7).   Gamma oscillations are associated with a number of 
cognitive processes, including perceptual and associative learning, object representation and 
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selective attention (51-54). These cognitive processes are often disrupted in HD patients (55-
62). This could be a consequence of abnormal brain oscillations seen in HD, including the 
increased gamma activity. In our study, a single treatment with either zolpidem or 
amitriptyline led to an immediate suppression of the abnormal low-gamma EEG oscillations 
in R6/2 mice during NREM sleep. Zolpidem reduced the abnormal low-gamma EEG 
oscillations by half while amitriptyline almost completely abolished them in R6/2 mice. 
Zolpidem enhances the GABAA receptor function by binding selectively to the omega-1 
receptor subtype (63). Therefore, it seems most likely that zolpidem decreased the abnormal 
low-gamma EEG oscillations in R6/2 mice by increasing GABAA-mediated inhibition of 
cortical activity. Whether this is achieved by acting specifically on layer V cortical neurons 
or just by increasing the overall GABAergic tone in the brain needs to be determined. 
Amitriptyline is primarily a serotonin-noradrenaline reuptake inhibitor, but it also acts on 
multiple neurochemical systems via serotonergic, adrenergic, histaminic, muscarinic, and 1 
receptors as well as glutamatergic NMDA receptors (64). Although the precise mechanism 
through which amitriptyline suppresses the abnormal EEG gamma oscillations in HD mouse 
brain is not known, it is likely that NMDA and/or muscarinic receptors are involved in this 
process. This is supported by the observation that in addition to GABA and glutamate, 
acetylcholine also plays an important role in gamma modulation through its muscarinic 
receptors (65). We predict that a complete and sustained suppression of abnormal brain 
oscillations might improve HD symptoms other than disrupted sleep. Consistent with this 
suggestion, it has been shown that motor function improved in an N171-82Q mouse model of 
HD after six weeks by amitriptyline treatment, started at the pre-symptomatic stage of the 
disease (66). Although, there are no clinical trials comparing the use of these drugs in HD 
patients, it is notable that amitriptyline (1 mg/kg/day), in combination with tetrabenazine (50 
mg/kg/day), eliminated psychotic symptoms in an atypical juvenile form of HD just after few 
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weeks of treatment (67). HD patients are treated with drugs with the preconception that the 
drugs will have the same effect in the HD patient as they do in the normal subject. Our data 
suggests that this may not be the case. A more thorough examination of the effect of 
hypnotics and antidepressants on HD brain function would clearly be of value. 
In summary, we show for the first time that sleep and EEG abnormalities specific to HD 
can be reversed in a mouse model of the disease after acute treatment with hypnotic drugs. 
Both zolpidem and amitriptyline normalized the amount of REM sleep and led to an 
immediate suppression of abnormal low-gamma EEG activity during NREM sleep in R6/2 
mice. Furthermore, our data demonstrate that sleep and EEG measures are useful indicators 
of drug-induced changes in mouse models of HD. Since HD mice, including the R6/2 mice 
studied here, largely recapitulate the changes in sleep and EEG seen in HD patients, they may 
be useful to evaluate the therapeutic potential of both existing and future treatment options. 
Critically, these results also provide evidence that at least some of the pathophysiological 
changes are not ‘hard-wired’ in HD mouse brain and can be modulated by drugs even at a 
late stage of the disease. 
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Figure legends 
Fig. 1. Zolpidem had a transient hypnotic effect in Huntington’s disease mice. The 
hourly amounts of wake (A, D), NREM sleep (B, E), and REM sleep (C, F) are shown in 14-
15 weeks old WT (A, B, C) and R6/2 (D, E, F) mice after a single treatment (arrow) with 
vehicle or zolpidem (20 mg/kg; i.p.) at dark onset (18:00). Data are presented as mean ± 
SEM. *P < 0.05 compared to vehicle. 
 
Fig. 2. Abnormal increase in REM sleep was partially suppressed by zolpidem in HD 
mice. Changes in the percentage of wake (A), NREM sleep (B) and REM sleep (C) are 
shown in WT and R6/2 mice during the 3 h period after treatment with vehicle or zolpidem 
(5, 10 and 20 mg/kg; i.p.) at dark onset (18:00). Data are presented as mean ± SEM. *P < 
0.05 compared to vehicle. 
 
Fig. 3. Zolpidem reduced the abnormal low-gamma EEG oscillations in R6/2 mice by 
half during NREM sleep. Changes in absolute (A, B) and relative (C, D) power values of 
EEG spectra during NREM sleep as shown in WT (A, C) and R6/2 (B, D) mice during the 2 
h period after vehicle or zolpidem (5, 10 and 20 mg/kg; i.p.) treatment. Enlarged images of 
absolute EEG power values in the low-gamma band outlined by the box in A and B are 
shown in the insets (A’, B’). The EEG power spectral values of WT and R6/2 mice were 
normalized after zolpidem treatment to the mean power spectral values (100 %) of vehicle-
treated WT mice (C, D). Data are shown as mean ± SEM in 1 Hz bins. *P < 0.05 compared 
to vehicle. 
 
Fig. 4. Zolpidem had no significant effect on REM sleep EEG in Huntington’s disease 
mice. Changes in absolute power values of EEG spectra during REM sleep as shown in R6/2 
Kantor et al. 
 25 
mice during the 2 h period after vehicle or zolpidem (5, 10 and 20 mg/kg; i.p.) treatment. 
Enlarged image of absolute EEG power values in the low-gamma band outlined by the box is 
shown in the inset (A’). Data are shown as mean ± SEM in 1 Hz bins. 
 
Fig. 5. Amitriptyline induced NREM sleep and abolished REM sleep for several hours. 
The hourly amounts of wake (A, D), NREM sleep (B, E), and REM sleep (C, F) are shown in 
16-17 weeks old WT (A, B, C) and R6/2 (D, E, F) mice after a single treatment (arrow) with 
vehicle or amitriptyline (20 mg/kg; i.p.) at dark onset (18:00). The dark period is shown as 
shaded area. Data are presented as mean ± SEM. *P < 0.05 compared to vehicle. 
 
Fig. 6. Amitriptyline increased NREM sleep and reduced REM sleep in a dose 
dependent manner. Changes in the percentage of wake (A), NREM sleep (B) and REM 
sleep (C) are shown in WT and R6/2 mice during the 6 h period after treatment with vehicle 
or amitriptyline (5, 10 and 20 mg/kg; i.p.) at dark onset (18:00). Data are presented as mean ± 
SEM. *P < 0.05 compared to vehicle. 
 
Fig. 7. Amitriptyline normalized the irregular low-gamma EEG oscillations seen in R6/2 
mice. Changes in absolute (A, B) and relative (C, D) power values of EEG spectra during 
NREM sleep as shown in WT (A, C) and R6/2 (B, D) mice during the 3 h period after vehicle 
or amitriptyline (5, 10 and 20 mg/kg; i.p.) treatment. Enlarged images of absolute EEG power 
values in the low-gamma band outlined by the box in A and B are shown in the insets (A’, 
B’). The EEG power spectral values of WT and R6/2 mice were normalized after 
amitriptyline treatment to the mean power spectral values (100 %) of vehicle-treated WT 
mice (C, D). Data are shown as mean ± SEM in 1 Hz bins. *P < 0.05 compared to vehicle. 
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Fig. 8. Putative changes in sleep-regulatory neural circuitry in R6/2 mice. (A) Globus 
pallidus (GP) neurons that are most active during wake and REM sleep receive inhibitory 
inputs from the striatum. GABAergic neurons in the external segment of GP (GPe) project 
directly to the cortex. (B) In symptomatic R6/2 mice, striatal neurons are hyperactive and 
GABAergic neurotransmission is decreased in GP. As a result, increased cortical activity 
occurs in R6/2 mice regardless of vigilance state that could account for the sleep and EEG 
abnormalities seen in these mice (see text for further details). GPi, internal globus pallidus. 
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Table 1. Vigilance state parameters in R6/2 and WT mice after vehicle or zolpidem treatment. 
Genotype WT R6/2 250 
Dose Veh 
(n = 7) 
5 mg/kg 
(n = 7) 
10 mg/kg 
(n = 7) 
20 mg/kg 
(n = 7) 
Veh 
(n = 9) 
5 mg/kg 
(n = 7) 
10 mg/kg (n = 9) 20 mg/kg 
(n = 8) 
Mean bout duration (min)         
WAKE 6.1 ± 1.1 4.7 ± 1.3 3.7 ± 0.6 3.2 ± 0.6a 5.0 ± 0.5 4.1 ± 0.4 3.0 ± 0.2 3.1 ± 0.4 
NREM sleep 2.6 ± 0.5 3.5 ± 0.4 3.9 ± 0.3 5.5 ± 0.9a 3.0 ± 0.2 4.0 ± 0.5 4.2 ± 0.4 4.3 ± 0.4 
REM sleep 1.3 ± 0.4 0.9 ± 0.1 1.0 ± 0.4 0.5 ± 0.2 1.3 ± 0.1 1.5 ± 0.1 1.0 ± 0.1 1.1 ± 0.1 
Number of bouts         
WAKE 21.7 ± 2.2 25.6 ± 3.8 24.4 ± 2.4 22.9 ± 3.0 19.8 ± 1.4 19.9 ± 2.4 22.8 ± 1.5 22.2 ± 1.3 
NREM sleep 22.4 ± 2.5 25.9 ± 3.7 25.0 ± 2.4 23.3 ± 2.9 24.8 ± 1.4 24.5 ± 2.4 26.1 ± 1.5 24.9 ± 1.4 
REM sleep 1.7 ± 0.6 1.3 ± 0.5 1.0 ± 0.4 1.3 ± 0.6 9.2 ± 1.2 7.8 ± 1.1 7.2 ± 1.0 6.1 ± 1.0 
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Table 2. Vigilance state parameters in R6/2 and WT mice after vehicle or amitriptyline treatment. 
Genotype WT R6/2 250 
Dose Veh 
(n = 7) 
5 mg/kg 
(n = 6) 
10 mg/kg 
(n = 6) 
20 mg/kg 
(n = 7) 
Veh 
(n = 6) 
5 mg/kg 
(n = 6) 
10 mg/kg 
(n = 6) 
20 mg/kg 
(n = 6) 
Mean bout duration (min)         
WAKE 5.2 ± 0.7 4.9 ± 0.9 3.0 ± 0.4 1.5 ± 0.3a 3.1 ± 0.4 3.9 ± 0.3 2.3 ± 0.4 1.7 ± 0.2 
NREM sleep 3.3 ± 0.2 4.8 ± 0.4 3.9 ± 0.4 4.6 ± 0.5 2.8 ± 0.4 3.9 ± 0.3 4.7 ± 0.6 6.4 ± 0.7a 
REM sleep 1.1 ± 0.2 0.9 ± 0.2 1.2 ± 0.5 0.3 ± 0.2 1.5 ± 0.1 1.5 ± 0.1 1.4 ± 0.1 1.1 ± 0.2 
Number of bouts         
WAKE 42.9 ± 4.0 36.3 ± 3.0 52.5 ± 3.2 61.4 ± 5.6 55.8 ± 9.3 38.2 ± 3.8 46.2 ± 4.6 43.8 ± 4.3 
NREM sleep 45.3 ± 3.7 38.5 ± 2.4 53.3 ± 3.6 61.6 ± 5.4 66.0 ± 8.4 49.5 ± 2.8 53.2 ± 4.2 47.0 ± 4.7 
REM sleep 5.6 ± 1.2 3.5 ± 1.3 1.7 ± 0.7 0.6 ± 0.3 20.8 ± 2.6 16.8 ± 1.5 11.7 ± 1.9a 3.3 ± 0.8a 
Mean duration and number of bouts in each state during the first 6 hours after vehicle or amitriptyline treatment. Results shown as mean ± SEM. aP < 0.05 compared to vehicle (Veh) treatment of the same genotype. 
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Fig 7 
 
